Medical Advocates

HCV Infection/Disease
  Investigational Drugs  
General Reports|
Cannabinoids
Anti-tumor Necrosis Factor-alpha
HEP1
Levovirin
Resiquimod

Thymosin alpha1
Viramidine
VX-950



 





 

HCV Main Page Main New/Newsworthy HCV Drugs Home Page      

Last Update:  February 03, 2008
 
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader


General Reports
 

      Conference Reports, Abstracts, and Posters
 

  CONFERENCE PRESENTATION
Future Therapy of Hepatitis C
McHutchison JG
[NIH Consensus Development Conference on  Management of Hepatitis C: 2002]

Report

Anti-tumor Necrosis Factor-alpha
 

      Journal Papers, Abstracts, and Commentaries

  Etanercept treatment for three months is safe in patients with rheumatological
manifestations associated with hepatitis C virus.

Marotte H, Fontanges E, Bailly F, et al   
Rheumatology
(Oxford). 2006 May 23;

Abstract

Cannabinoids
 

      Journal Papers, Abstracts, and Commentaries

  Reefer madness? Assessing the effects of cannabinoids with a less jaundiced eye
Friedman SL.
J Hepatol.
2006 Oct 30;

Abstract

HEP1
 

     Journal Papers, Abstracts, and Commentaries

  Treatment of hepatitis C virus infection with human ezrin peptide one (HEP1) in HIV infected
patients.

Salamov G, Holms R, Bessler WG, Ataullakhanov R.

Arzneimittelforschung. 2007;57(7):497-504.
Abstract

Levovirin
 

      Journal Papers, Abstracts, and Commentaries

  Prospects for hepatitis C virus therapeutics: levovirin and viramidine as improved derivatives
of ribavirin.

Watson J.
Curr Opin Investig Drugs 2002 May;3(5):680-3  

Abstract

Resiquimod
 

      Journal Papers, Abstracts, and Commentaries

  Oral resiquimod in chronic HCV infection: Safety and efficacy in 2 placebo-controlled,
double-blind phase IIa studies

Pockros PJ, Guyader D, Patton H, Tong MJ, et al
J Hepatol. 2007 May 4;

Abstract

Thymosin alpha1
 

      Journal Papers, Abstracts, and Commentaries

  Thymosin alpha1
Billich A.
Curr Opin Investig Drugs 2002 May;3(5):698-707

Abstract   

VX-950
 

      Journal Papers, Abstracts, and Commentaries

  Prospects for hepatitis C virus therapeutics: levovirin and viramidine as improved
derivatives of ribavirin.

Watson J.
Curr Opin Investig Drugs 2002 May;3(5):680-3  
Abstract

Viramidine
 

      Journal Papers, Abstracts, and Commentaries

  Rapid Decline of Viral RNA in Hepatitis C Patients Treated With VX-950: A Phase Ib,
Placebo-Controlled, Randomized Study.
Reesink HW, Zeuzem S, Weegink CJ, et al
Gastroenterology
. 2006 Oct;131(4):997-1002.
Abstract


HCV Main Page Main New/Newsworthy HCV Drugs Home Page      

HCV Investigational Drugs